Valuation: MaaT Pharma

Market Cap 47.39M 54.71M 44.81M 40.57M 76.14M 5.25B 76.72M 535M 206M 2.66B 206M 201M 8.49B P/E 2026 *
-1.32x
P/E 2027 * -2.26x
Enterprise Value 58.7M 67.76M 55.5M 50.25M 94.31M 6.5B 95.02M 662M 255M 3.3B 255M 249M 10.51B EV / Sales 2026 *
6.02x
EV / Sales 2027 * 2.84x
Free-Float
36.85%
Yield 2026 *
-
Yield 2027 * -
1 day-57.06%
1 week-62.50%
Current month-63.51%
1 month-62.63%
3 months-63.27%
6 months-84.30%
Current year-77.55%
1 week 1
Extreme 1
2.88
1 month 1
Extreme 1
3.4
Current year 1
Extreme 1
8.62
1 year 1
Extreme 1
8.62
3 years 1
Extreme 1
9.96
5 years 1
Extreme 1
14.4
10 years 1
Extreme 1
14.4
Manager TitleAgeSince
Chief Executive Officer - 2013-12-31
Director of Finance/CFO 59 2024-10-31
Chief Tech/Sci/R&D Officer - 2024-06-23
Director TitleAgeSince
Director/Board Member - 2013-12-31
Director/Board Member 57 2013-12-31
Chairman - 2015-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/28/26 Buy

Founder

2,000 0.0106%
1/29/26
Seventure Partners SA
SellCompany 25,423 0.1356%
1/28/26
Seventure Partners SA
SellCompany 57,964 0.3091%
Change 5-day change 1-year change 3-year change Capi.($)
-57.06%-62.50%-75.68%-83.12% 54.69M
-1.38%+2.23%+48.54%+100.96% 70.24B
-1.04%-1.22%+33.27%+74.98% 62.63B
-4.29%-3.98%-16.22%+350.66% 27.36B
+0.16%+1.53%+34.92%+17.47% 25.71B
-2.20%-2.00%-1.22%-14.48% 24.83B
+1.61%+0.42%+19.44%-20.66% 19.52B
+1.26%-9.06%+165.21%+308.08% 15.51B
-3.91%-5.71%-8.71%+521.92% 14.66B
-5.54%+0.69%-8.13%+830.48% 14.69B
Average -7.24%-2.47%+19.14%+208.63% 27.52B
Weighted average by Cap. -1.53%-0.65%+31.28%+166.05%

Financials

2026 *2027 *
Net sales 9.75M 11.26M 9.22M 8.35M 15.67M 1.08B 15.78M 110M 42.33M 548M 42.28M 41.35M 1.75B 28.88M 33.34M 27.31M 24.72M 46.4M 3.2B 46.75M 326M 125M 1.62B 125M 122M 5.17B
Net income -31.69M -36.59M -29.97M -27.13M -50.92M -3.51B -51.31M -358M -138M -1.78B -137M -134M -5.68B -15.31M -17.68M -14.48M -13.11M -24.6M -1.7B -24.78M -173M -66.47M -860M -66.4M -64.92M -2.74B
Net Debt 11.3M 13.05M 10.69M 9.68M 18.16M 1.25B 18.3M 128M 49.08M 635M 49.02M 47.93M 2.02B 34.5M 39.83M 32.62M 29.53M 55.43M 3.82B 55.85M 389M 150M 1.94B 150M 146M 6.18B
Logo MaaT Pharma
MaaT Pharma is a late-stage biotechnology company and a leader in the development of intestinal microbiota-based drugs designed to modulate the immune system of cancer patients and improve their survival. A pioneer in its field, MaaT Pharma is developing the first immunomodulatory drug candidate based on intestinal microbiota in oncology, currently in phase 3 clinical evaluation. Thanks to its proprietary pooling (combining donations of healthy microbiota) and microbial co-culture technologies, MaaT Pharma is developing standardised drugs with high bacterial diversity, aimed at improving the survival of cancer patients.
Employees
56
Date Price Change Volume
26-09-15 1.080 -57.06% 444,282
26-09-14 €2.515 -8.04% 79,774
26-09-11 €2.735 -1.97% 33,087
26-09-10 €2.790 +5.08% 38,283
26-09-09 €2.655 -5.18% 34,428
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.515EUR
Average target price
6.100EUR
Spread / Average Target
+142.54%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MAAT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!